KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amgen (AMGN) EPS (Weighted Average and Diluted) (2016 - 2026)

Amgen has reported EPS (Weighted Average and Diluted) over the past 18 years, most recently at $3.34 for Q1 2026.

  • For Q1 2026, EPS (Weighted Average and Diluted) rose 4.37% year-over-year to $3.34; the TTM value through Mar 2026 reached $14.38, up 31.2%, while the annual FY2025 figure was $14.23, 88.23% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q1 2026 was $3.34 at Amgen, up from $2.46 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $5.93 in Q3 2025 and troughed at -$0.21 in Q1 2024.
  • A 5-year average of $2.93 and a median of $2.68 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 103.98% in 2024 and later soared 1623.81% in 2025.
  • Year by year, EPS (Weighted Average and Diluted) stood at $3.0 in 2022, then plummeted by 52.33% to $1.43 in 2023, then fell by 18.88% to $1.16 in 2024, then skyrocketed by 112.07% to $2.46 in 2025, then skyrocketed by 35.77% to $3.34 in 2026.
  • Business Quant data shows EPS (Weighted Average and Diluted) for AMGN at $3.34 in Q1 2026, $2.46 in Q4 2025, and $5.93 in Q3 2025.